Consumer Health | Medical Devices | Pharmaceuticals

JOHNSON & JOHNSON INNOVATION | 1 “At Johnson & Johnson Innovation, our goal is to bring forth highly differentiated healthcare solutions that extend and improve lives. To do this, we collaborate with innovators and entrepreneurs all over the world to change the trajectory of health for humanity.

Paul Stoffels, M.D. Vice Chairman of the Executive Committee and Chief Scientific Officer Johnson & Johnson

JOHNSON & JOHNSON INNOVATION | 2 When I took the helm at a small biotechnology company, Tibotec, my goal was to develop a new molecular entity that would provide a breakthrough in combating multidrug-resistant forms of HIV. I approached this opportunity to change the way HIV/AIDS is treated—not just as a physician in Africa where I started my career in medicine—but also as a scientist, an innovator and an entrepreneur.

However, I quickly discovered that the Francisco, Boston, London and solutions that extend and improve task of bringing new and differentiated Shanghai—our aim was to contribute lives, not just through therapeutics, medicines to patients globally is not to the robust regional innovation but also medical devices, consumer an easy one. It requires more than ecosystems around the world and products and integrated technology- great science, tenacity and a good to do so by meeting the needs of enabled solutions. We also are business plan. Without the help of entrepreneurs and scientists working committed to being champions of strong collaborators who can offer in the areas of medical technologies, science and engaging more people complementary expertise, it is consumer healthcare technologies across generations and geographies nearly impossible. and therapeutics. Today, Johnson & to see the unlimited opportunities that Johnson Innovation brings together science brings. Today, Tibotec is part of Johnson & business development, venture Johnson. The relationship between investment, incubation and research To do this, we identify the right Tibotec and Johnson & Johnson has and development (R&D) resources partnerships and deal structures and led to the successful development from across our company to advance allow innovators to leverage the many and launch of transformative HIV science and technology at all stages resources of Johnson & Johnson. medications that have improved of innovation. Providing the right kind of support for the quality of life and significantly new ideas is critical to driving innovation extended the lives of people all over Our goal is to unleash the power of and achieving our goals to transform the world who are living with HIV. science and technology to advance world health. We look forward to getting the health of everyone, everywhere. to know you and working with you to When we launched Johnson & Fundamentally, Johnson & Johnson push the boundaries of what science Johnson Innovation—first with Innovation is about bringing forth and medicine can achieve. Innovation Centers in South San highly differentiated new healthcare

JOHNSON & JOHNSON INNOVATION | 3 Our “Our mission is to create the leading global innovation network to generate transformational healthcare solutions approach through value-creating partnerships.

VISION:

Positively impact human health through innovation. William N. Hait, M.D., Ph.D. Global Head, Johnson & Johnson External Innovation

JOHNSON & JOHNSON INNOVATION | 4 Our network

Areas of interest 06 Research & development 17

Innovation acceleration 08 Cross-Sector innovation 21

Company incubation 10 Global public health 23

Strategic investing 13 Connect with us 25

Business development 15 Our global reach 34

JOHNSON & JOHNSON INNOVATION | 5 Areas of interest

We are looking for transformational ideas that align with priorities in our pharmaceutical, consumer health and medical devices businesses as well as innovations that converge across these sectors. In each category, we focus on specific areas of interest that have the greatest potential to improve the lives of patients and consumers, as well as contribute to our business.

JOHNSON & JOHNSON INNOVATION | 6 Pharmaceuticals PULMONARY HYPERTENSION (PH) Consumer Health • Pulmonary Arterial Hypertension CARDIOVASCULAR & METABOLISM SELF CARE • PH adjacencies, including Idiopathic • Cardiovascular and Thrombosis • Allergy Pulmonary Fibrosis • Retinal Disease • Diagnostics & Personalization • Metabolism/NASH PLATFORMS • Digital Therapeutics • • Renal Disease Small Molecule & Protein Therapeutics • Naturals & Microbiome • RNA Therapeutics, Gene Therapy • Pain IMMUNOLOGY • Cellular & Viral Therapeutics • Smoking Cessation • Gastroenterology • Data Science & Analytics • Rheumatology SKIN HEALTH • Immuno Dermatology • Acne • IL-23 Pathway Medical Devices • Diagnostics & Personalization MED TECH & VISION • Digital Skin Health INFECTIOUS DISEASES & VACCINES • 3D Printing • Naturals • Viral Hepatitis & Adjacent Liver Diseases • Cardiovascular • Skin Rejuvenation • Prevention & Treatment of Viral & Bacterial • Respiratory Infections Contact Lens • Infection Prevention • Adjuvants, Novel Viral Vectors & Cross-Sector Vaccine Technologies • Neurovascular BEHAVIORAL SCIENCE • Obesity NEUROSCIENCE IMMUNOSCIENCES • Osteoarthritis • Mood Disorders GLOBAL PUBLIC HEALTH • Robotic Surgery and Digital Solutions • Neurodegenerative Disorders, including HEALTH TECHNOLOGY Multiple Sclerosis • Surgical Oncology LUNG CANCER • Glutamatergic Pathway Diseases • Vision Surgery MICROBIOME • Schizophrenia PREDICTIVE ANALYTICS ONCOLOGY • Prostate Cancer • Hematologic Malignancies • Solid Tumor Targeted Therapy • Immuno-Oncology

JOHNSON & JOHNSON INNOVATION | 7 Innovation acceleration

Johnson & Johnson Innovation Centers are focused on accessing innovation from all sources from inception to early stages of development. We are seeking innovations with the potential to make a transformational impact on the health and lives of people and patients around the globe.

Innovation Collaborations 4 Innovation Centers on three continents

580+ collaborations executed over the past eight years

$1B+ capital deployed since 2013

JOHNSON & JOHNSON INNOVATION | 8 Our innovation centers Network locations The Johnson & Johnson Innovation Centers In addition to our Innovation Centers, we have New Venture Lead “Scouts” and identify early stage transformational healthcare Partnering Offices embedded in further innovation hot spots across the world. solutions from academics or startup companies who want to partner with us to accelerate Our Scouts are colocated with the local market Operating Companies across EMEA their novel program. Our Innovation Centers and APAC. Our Partnering Offices (JJIPO) are public-private partnerships between are located around the globe in the central Johnson & Johnson Innovation, a host university and the relevant state government life sciences hot spots of South San Francisco, partner. JJIPOs are designed to support life sciences innovators with a geographical Boston, London and Shanghai, with a remit reach across the state to accelerate health innovation for future consideration of to source collaborations across their collaboration by the Johnson & Johnson Family of Companies. JJIPOs host bespoke geographic regions. training, mentoring, roundtables and networking events to support the local innovation ecosystem to achieve commercialization success. Our current JJIPO locations are in Each Innovation Center houses science and Brisbane and Melbourne, Australia. technology experts, and has full and broad dealmaking and transaction capabilities. This “hub-and-spoke” model enables us to extend our innovation network deep into They create bespoke deal structures and the local ecosystem. bring together resources from across our company, including:

• Early-stage research funding and collaboration • Licensing • Investments across the spectrum from seed to later-stage private and public financing • New company creation

The teams located at the Johnson & Johnson Innovation Centers are interested in collaborating with regional entrepreneurs at startup companies, universities and institutes who are developing early-stage innovations that are pre-proof of concept in humans across a broad healthcare spectrum, including pharmaceuticals, medical devices and consumer health sectors.

JOHNSON & JOHNSON INNOVATION | 9 Company incubation We understand the challenges of getting a life sciences company up and running, which is why Johnson & Johnson Innovation provides a number of company incubation options for our partners around the globe, through our JLABS and JPODs.

Incubators 700+ companies, including current resident companies and alumni 13 locations around the globe 192+ companies with at least one collaboration with Johnson & Johnson

JOHNSON & JOHNSON INNOVATION | 10 In eight years, Johnson & Johnson A big company platform for spectrum including pharmaceutical, Innovation—JLABS has an inspiring emerging healthcare companies medical devices, consumer health and story to tell about going global and health tech sectors. the influence the program and its JLABS is a global network of open companies are having on the innovation innovation ecosystems, enabling and Our JLABS are in San Diego and San ecosystem—our hope was to empower empowering innovators to create and Francisco/Bay Area (CA), Cambridge and and enable the brightest minds to accelerate the delivery of life-saving, life- Lowell (MA), Houston (TX), New York City tackle some of the world’s most enhancing health and wellness solutions to (NY), Toronto (Canada), Beerse (Belgium), challenging problems in health. patients around the world. JLABS achieves Shanghai (China) and a new location opening this by providing the optimal environment in Washington, D.C. in 2021. We’ve not only experienced significant for emerging companies to catalyze growth—from one to 13 locations across growth and optimize their research and the globe—but we also now count 700+ development. By opening them to vital companies in the JLABS ecosystem industry connections, educational programs who have secured $43B+ in upfront and a capital-efficient, flexible platform, and contingent funding to help tackle JLABS provides an optimal environment some of today’s greatest healthcare for life sciences companies to transform challenges and advance solutions for the scientific discoveries of today into patients. We know that great ideas can the breakthrough healthcare solutions come from anywhere, but that success of tomorrow. is only achieved by expanding access to resources, education, mentoring At JLABS we value great ideas and are and financing—all key to reaching our passionate about removing obstacles to common goals in the life science space. success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare

JOHNSON & JOHNSON INNOVATION | 11 QuickFire challenges across the globe CDI @ TMC The QuickFire Challenges are a global crowd-sourcing The Center for Device Innovation at the Texas Medical platform for the innovator community to apply diverse Center (CDI @ TMC) is a collaboration that aims to perspectives to provide novel solutions. Winning accelerate end-to-end development of breakthrough companies can be awarded funding, mentorship or the medical devices. CDI’s state-of-the-art engineering opportunity to become residents at JLABS to move their capabilities are partnered with TMC’s scientific and science forward. To date, over 54 QuickFire Challenges clinical facilities to accelerate new medical technologies have launched with more than 4,700 applications and 108 from concept through commercialization. CDI is home innovators have received over $9 million in awards. to R&D staff of the Johnson & Johnson Medical Devices Companies and is used to accelerate select internal JPOD projects and strategically aligned ventures of startup A JPOD is a networking hub embedded in innovation hot partner companies. spots to better connect regional innovators to the global Johnson & Johnson Family of Companies. A JPOD includes a secure telecommunications conferencing system and is host to training, mentoring and commercialization programs designed to equip startups with a mix of resources to help enable their success. Our JPOD locations are in Philadelphia (PA) and Boston (MA) in the USA.

JOHNSON & JOHNSON INNOVATION | 12 Strategic investing

Johnson & Johnson Innovation—JJDC (JJDC) is the strategic venture capital arm of Johnson & Johnson and a long-term investment partner to healthcare entrepreneurs.

Venture Funding 47+ year legacy

45+ investments in 2020

$500M+ capital deployed in 2020

JOHNSON & JOHNSON INNOVATION | 13 Driving innovation through We invest at all stages, ranging from seed venture investing funding and Series A investments in the earliest-stage startups to Series B investments JJDC has invested in hundreds of emerging and beyond in more mature companies, each life sciences companies developing healthcare deal customized to fit the opportunity. We solutions in areas of strategic interest to the make private investments in public equity to Johnson & Johnson Family of Companies and it support licensing deals. plays a key role in the Company’s strategy to bring new healthcare products to the people At JJDC, we believe strongly in value-add who need them. investing and play an active role in the companies in which we invest. Through this, Working closely with the Innovation Centers, we provide strategic direction and access to JJDC has visibility to a wide range of opportunities internal experts across the Johnson & Johnson across a broad healthcare spectrum including Family of Companies. Our ultimate goal is pharmaceutical, medical devices and consumer to help grow the pipeline of the Johnson & sector investing. JJDC does not believe in a Johnson Family of Companies with innovative one-size-fits-all approach. We understand that products that benefit patients. each company is unique and requires an equally distinct investment strategy.

JOHNSON & JOHNSON INNOVATION | 14 Business development

With a strong vision, a culture of caring and an intention to invest in the future, we are committed to take partnering for health and well-being to a new level. At Johnson & Johnson, the decentralized way we operate our businesses combines the best qualities of smaller companies—an entrepreneurial drive for growth and proximity to customers—with the resources, know-how and investment capital of a well-respected Fortune 500 company. This strategic approach gives us a strong sense of ownership and an agility and accountability seldom seen in large multinational corporations. Our goal is to form an active partnership where we can bring the full strength of Johnson & Johnson to bear to create a long and valuable relationship.

JOHNSON & JOHNSON INNOVATION | 15 Midsize to large biotech Established Medical Established Consumer and established pharmaceutical Devices companies Health companies companies—Janssen At Johnson & Johnson Medical Devices At Johnson & Johnson Consumer Health, business development Companies, we are using our breadth, we are rooted in science and we are The Johnson & Johnson Innovation—Janssen scale and experience to reimagine the way proud that our products are endorsed by Business Development team pursues partner healthcare is delivered and to help people professionals. Nearly one billion people opportunities that will accelerate the live longer, healthier lives. In a radically around the world use our products each creation of healthcare solutions that changing environment, we are making day. Our goal is to provide consumers with improve people’s lives around the world. connections across science and technology transformative products, and our experts We seek to create value in six defined to combine our own expertise in surgery, within the Innovation Centers, Consumer therapeutic areas: Cardiovascular & orthopaedics, vision and interventional Business Development and JJDC are actively Metabolism; Immunology; Infectious solutions with the big ideas of others to exploring the best science and technology Diseases & Vaccines; Neuroscience; design and deliver doctor and patient- to support consumer healthcare businesses. Oncology; and Pulmonary Hypertension. centric products and solutions. As pioneers We are interested in novel, game-changing Janssen Business Development is very in medical devices, we continually focus on ingredients as well as completely new active in acquiring assets, companies elevating the standard of care—working to products (including devices), business and technologies as well as entering into expand patient access, improve outcomes, models and solutions. Our collaborators have strategic collaborations, including joint reduce health system costs and drive value. the opportunity to leverage our strong R&D, ventures, development collaborations, From restoring vision and mobility, to marketing, regulatory and manufacturing commercial partnerships with established providing tools for safe and effective surgery, capabilities, as well as our global footprint. pharmaceutical companies and midsize to to enabling those with debilitating conditions These capabilities—honed through the large biotechnology companies. Working to get the best treatment, we are helping development of some of the best-known with Janssen Business Development gives people live fuller lives and paving the way to brands in the world—are part of you access, resources, expertise and a healthier future for everyone, everywhere. each conversation. commitment that you simply can’t find We are in this for life. anywhere else.

JOHNSON & JOHNSON INNOVATION | 16 Research & development Johnson & Johnson is a broadly based global healthcare company with expertise in all stages of research and development spanning large- and small-molecule therapeutics, multi-specific protein therapeutics, cell therapy, gene therapy, RNA therapeutics, vaccines, medical devices and consumer health products. We work with our collaborators across our therapeutic areas to provide a wide range of R&D support, from discovery and early development through clinical trial design and regulatory strategy.

JOHNSON & JOHNSON INNOVATION | 17 Johnson & Johnson Medical Devices Johnson & Johnson Consumer research & development Health research & development At the Johnson & Johnson Medical Devices Johnson & Johnson Consumer Health, known for Companies, we are building a better health its iconic brands, is one of the largest and most experience and enabling people everywhere to live scientifically-driven consumer health businesses in life more fully. We combine our breadth and depth the world. Most of our products are endorsed as across surgical and orthopaedic technologies, eye #1 in their category by healthcare professionals. health and interventional solutions with the scale We are strategically organized around three and expertise of Johnson & Johnson to meet the consumer need areas, i.e., Self Care, Skin Health changing needs of patients, health providers and our and Essential Health. We deliver products and world. We are addressing healthcare’s most pressing solutions grounded in deep consumer insights and challenges and creating solutions for a lifetime of backed by strong research. We seek important new overall health. As one of the most comprehensive technologies and solutions that can be accelerated medical devices businesses in the world, we are to consumers through co-creation with external working to design and disrupt every major stage of innovators and our internal R&D teams. With a focus the healthcare experience. We focus on creating on our key strategic areas, our External Innovation breakthrough innovations, advanced medical team, Business Development team and broader technologies and patient-centered solutions that Johnson & Johnson Innovation organization seek enable smarter health, better value and improved opportunities from around the world—no matter outcomes. We aim to improve the health experience where the idea might be. for patients, physicians, health systems and others along the spectrum of care.

JOHNSON & JOHNSON INNOVATION | 18 Janssen Pharmaceutical We recognize that the early stage external ecosystem research & development is thriving—only 6% of the industry’s R&D pipeline is now held by the top 10 pharmaceutical companies At Janssen R&D, our mission is to use heart, science and that to thrive in tomorrow’s marketplace, a and ingenuity to create transformational medicines successful large pharmaceutical company must to improve the health of humanity. Fueled by this understand how to be part of this ecosystem—not mission, we have grown twice as fast as the rest of compete against it. the pharmaceutical industry to become the largest pharmaceutical company in the US. This success is Our reputation as a partner is second to none. driven by 19 new products approved since 2011 that Our track record and commitment to the broad impact the lives of many patients and their families community of innovators is high, with 500+ active and communities. And, we anticipate to file for opportunities and collaborations through the multiple more highly meaningful medicines in the next four Johnson & Johnson Innovation nodes. We have great to five years. We are divided into six therapeutic respect for the world’s scientists and the companies areas1 that run disease and biological pathway that pursue their insights. We also respect their focused portfolios, which are fueled by world-class investors’ objectives. functions in Discovery, Product Development & Supply, Development Operations, and Regulatory We have a strong reputation for being forward- Affairs. In our therapeutic areas, we have true end- looking, open minded to new ideas, and respectful to-end accountability, from an idea that seeds a of good ideas from wherever they come. But we also discovery project through the last label change know and have an ineffable and exquisite sense of prior to loss of exclusivity in the market. Such an which platforms and approaches hold promise, and organizational span permits frictionless translation which don’t among our scientists and clinicians. of insight, both in the forward lab-to-clinic direction, and reverse translation from the clinic-back-to-the- lab, inspiring new programs.

1. Cardiovascular & Metabolism, Immunology, Infectious Diseases and Vaccines, Neuroscience, Oncology, Pulmonary Hypertension

JOHNSON & JOHNSON INNOVATION | 19 We strive to blur the line between internal and external: Our scientists sometimes invent our own therapeutics and platforms. We sometimes license technology, and oftentimes collaborate, bringing complementary skills together. Sometimes we will incubate a company. Sometimes we will acquire an asset or company, and sometimes we will cleverly finance an asset through newcos, Joint Ventures and other mechanisms.

Across all of these partnerships, our fundamental belief has always been to seek out actionable biology, technology that enables translation of this biology into a medicine and special people. We are also actively looking to find novel modalities that offer the promise to effectively modulate difficult targets (e.g., gene therapy, RNA therapeutics) and collaborations leveraging data science capabilities to unlock disease insights and deliver better patient outcomes. We work with teams internally and across the world We are committed to building deep, lasting “ to translate breakthroughs in science and technology relationships with the exceptional individuals and companies we partner with, where we can bring into transformational medicines that change the lives the full strength of Janssen R&D to help you create of patients, their families and communities. and deliver transformational medicines. We are a participant, a partner, an accelerator within this Mathai Mammen, M.D., Ph.D. vibrant ecosystem. We believe in enabling your Global Head, Janssen Research & Development success. We believe in you.

JOHNSON & JOHNSON INNOVATION | 20 Cross-Sector innovation

The Lung Cancer Initiative at Johnson & Johnson The cross-sector Lung Cancer Initiative (LCI) at Johnson & Johnson is dedicated to transforming the standard of care for this devastating disease. The vision for the LCI is to develop solutions that prevent, intercept and cure lung cancer, enabling a future without this devastating disease. By focusing on where the best science and innovation is being developed anywhere in the world, the LCI aims to eliminate lung cancer one patient at a time by developing holistic solutions through pharmaceutical, medical device and consumer sectors.

JOHNSON & JOHNSON INNOVATION | 21 Accelerating a world without disease The World Without Disease Accelerator (WWDA) is a unique enterprise R&D group aligned with global commercial expertise and focused on the discovery, development and delivery of disruptive products/technologies, business models and partnerships to advance the elimination of disease. The WWDA brings together distinct enabling capabilities in areas including the microbiome, immunosciences, predictive analytics and behavioral sciences to seed transformative growth opportunities and catalyze a paradigm shift in prevention, interception and cure strategies and solutions.

Health technology Digital is creating unprecedented opportunities to reimagine how care is accessed, delivered, managed, and experienced. We want to collaborate with technology and digital health innovators around the world to create products and programs that profoundly change the trajectory of human health.

JOHNSON & JOHNSON INNOVATION | 22 Global public health

Upholding the 130-year heritage of Johnson & Johnson, we are taking on the toughest challenges to advance healthcare for the world’s most vulnerable and underserved populations.

JOHNSON & JOHNSON INNOVATION | 23 The world has made significant progress in providing Areas of interest healthcare, yet major gaps remain, and bolder, smarter TB AND OTHER MYCOBACTERIA approaches are needed to overcome the drastic Expanding access and uptake of existing regimens for multidrug-resistant inequity in access to care—now. TB (MDR-TB), developing simplified treatment regimens, novel molecular As one of the world’s largest healthcare companies, approaches, companion diagnostics and leprosy elimination tools. we are driven to enable better health for more people in more places. Through a dedicated global public HIV health (GPH) organization that includes research and Novel and simplified treatment tools, including long-acting injectable development, global access strategies and programs, formulations, approaches for latent HIV, point-of-care diagnostics and and local operations, we put the world’s most innovative prevention strategies. vulnerable and underserved at the heart of everything we do—measuring our success in lives improved. EMERGING PATHOGENS We support innovation across the continuum of care Dengue prevention and treatment; COVID-19 treatment (screening to help develop the new technologies, treatments and and repurposing), emerging pathogens and pandemic preparedness; vaccines needed to make progress against the world’s AMR opportunities. most life-threatening diseases. Recognizing we can’t do this alone, we seek to bring together public and private resources, invest in science both inside and outside of OTHER APPLICATIONS our walls and offer access to our R&D capabilities. Digital health, data sciences and artificial intelligence platforms targeting GPH diseases; opportunities for global public health disease prevention and Ultimately, we hope to do our part to close the gap of elimination, including vaccines. inequity and pave the way to a healthier future for the world’s most vulnerable and underserved populations. SHARING OUR MOLECULAR LIBRARIES Johnson & Johnson, in partnership with WIPO Re:Search, is proud to make available its JumpstARter library to drug discovery researchers in order to identify and advance promising drug candidates to fight neglected infectious diseases. The library includes a diverse collection of 80,000 high-quality GLOBAL GLOBAL ACCESS LOCAL drug-like small molecules and compound fragments created to “jump-start” R&D & PROGRAMS OPERATIONS drug discovery collaborations.

JOHNSON & JOHNSON INNOVATION | 24 External Innovation Connect with us Leadership contacts

External Innovation

William N. Hait, M.D., Ph.D. Global Head, Johnson & Johnson Flexible deal HOW CAN WE Commercial & External Innovation structures access expertise PARTNER? E: [email protected]

Strategic Investing R&D Funding collaboration & & investing acceleration Chris Picariello

Company President, JJDC incubation E: [email protected] & facilities

Company Incubation THREE STRONG SECTORS Melinda Richter Global Head, JLABS E: [email protected] Consumer Medical Pharmaceuticals Health Devices

CROSS-SECTOR JOHNSON & JOHNSON INNOVATION | 25 Innovation Center, South San Francisco, CA, USA Cross Sector Innovation

Stacy Feld Avrum Spira, M.D., M.S.C. Head, Johnson & Johnson Innovation, Global Head, World Without Disease Accelerator West North America, Australia & New Zealand and The Lung Cancer Initiative at Johnson & Johnson E: [email protected] E: [email protected]

Innovation Center, London, UK Global Public Health Nerida Scott, Ph.D. Head, Johnson & Johnson Innovation, Martin Fitchet Europe, Middle East & Africa Global Head, Global Public Health E: [email protected] E: [email protected]

Innovation Center, Boston, MA, USA Health Technology

Michal Preminger, Ph.D., MBA Oliver Hsiang Head, Johnson & Johnson Innovation, Global Head, Johnson & Johnson East North America Health Technology Innovation E: [email protected] E: [email protected]

Innovation Center, Shanghai, China

Dan Wang, M.D., MBA, MPH Head, Johnson & Johnson Innovation, Asia Pacific E: [email protected]

JOHNSON & JOHNSON INNOVATION | 26 Janssen R&D Leadership contacts

Janssen Research & Development Janssen Business Development

Mathai Mammen, M.D., Ph.D. Patrick Verheyen Global Head, Research & Development Global Head, Janssen Business Development

Cardiovascular & Metabolism Immunology

James F. List, M.D., Ph.D. David M. Lee, M.D., Ph.D. Global Therapeutic Head, Global Therapeutic Head, Immunology Cardiovascular & Metabolism EARLY STAGE – INNOVATION CENTERS EARLY STAGE – INNOVATION CENTERS Jennifer Towne, Discovery Mark Erion, Discovery E: [email protected] E: [email protected] Jackie Benson, West US & ANZ, Asia Pacific Charles Bridges, Chief Technology Officer E: [email protected] and Head of Cross Enterprise Innovation E: [email protected] Jarrat Jordan, East US E: [email protected] Liangsu Wang, West US & APAC E: [email protected] Pascale Marty-Ethgen, East US E: [email protected] Jim Tobin, East US E: [email protected] Jason Witherington, Europe Lars Erwig, EMEA E: [email protected] E: [email protected] Jennifer Bell, Europe E: [email protected] LATE STAGE – JBD Sarah Brennan LATE STAGE – JBD E: [email protected] Johan Verbeeck Scott Lundeen, Scientific Licensing E: [email protected] E: [email protected] Simon Blake, Scientific Licensing Lisa Norquay, Scientific Licensing E: [email protected] E: [email protected]

JOHNSON & JOHNSON INNOVATION | 27 Infectious Diseases & Vaccines Neuroscience

James Merson, Ph.D. Bill Martin, Ph.D. Global Therapeutic Head, Infectious Diseases Global Therapeutic Head, Neuroscience

EARLY STAGE – INNOVATION CENTERS Johan Van Hoof, M.D. David Bredt, Discovery Global Therapeutic Head, Vaccines E: [email protected] Guy Seabrook, Global, West US & ANZ EARLY STAGE – INNOVATION CENTERS E: [email protected] Haifeng Cui, Asia Pacific Eric Schaeffer, East US E: [email protected] E: [email protected] Kenny Simmen, Global & Europe John Issac, EMEA E: [email protected] E: [email protected] Nicola La Monica, US & ANZ E: [email protected] LATE STAGE – JBD Isabel Najera, Discovery, Therapeutics Lucinda Warren E: [email protected] E: [email protected] Jan Poolman, Discovery & Early Gregor Macdonald, Scientific Licensing Development, Bacterial Vaccines E: [email protected] E: [email protected] Hanneke Schuitemaker, Discovery & Early Development, Viral Vaccines E: [email protected]

LATE STAGE – JBD Timothy Herpin E: [email protected] Kristien Bonroy, Scientific Licensing E: [email protected]

JOHNSON & JOHNSON INNOVATION | 28 Oncology Pulmonary Hypertension

Peter Lebowitz, M.D., Ph.D. Neil Davie, Ph.D. Global Therapeutic Head, Oncology Global Therapeutic Head, Pulmonary Hypertension

EARLY STAGE – INNOVATION CENTERS EARLY STAGE – INNOVATION CENTERS Joseph Erhardt, Discovery Lars Erwig, EMEA E: [email protected] E: [email protected] Sylvaine Cases, West US & ANZ LATE STAGE – JBD E: [email protected] Nicholas Franco Bob Radinsky, East US E: [email protected] E: [email protected] Dr. Jörg Läeuffer, Scientific Licensing Sonal Patel, Europe E: [email protected] E: [email protected] Stefan Hart, Asia Pacific E: [email protected]

LATE STAGE – JBD Deborah Watson E: [email protected] Mike Rycyzyn, Scientific Licensing E: [email protected]

JOHNSON & JOHNSON INNOVATION | 29 Data Science

Najat Khan, Ph.D. EARLY STAGE – INNOVATION CENTERS Chief Data Science Officer Paul Ashley, EMEA Global Head, Strategy & Operations, Janssen R&D E: [email protected] Maya Tsukernik, Strategy & Operations, Emma Huang Janssen R&D Data Science E: [email protected] E: [email protected] LATE STAGE – JBD Joel Greshock, Oncology E: [email protected] Deborah Pfennig E: [email protected] Pam Bradt, Immunology, Janssen R&D Data Science E: [email protected] Gayle Wittenberg, Neuroscience, Janssen R&D Data Science E: [email protected] Joanne Foody, Cardiovascular & Metabolism and Pulmonary Hypertension, Janssen R&D Data Science E: [email protected] Lilian Li, Infectious Diseases, Janssen R&D Data Science E: [email protected] Sid Jain, Global Development, Janssen R&D Data Science E: [email protected] Hugo Ceulemans, Discovery (Computational Chemistry) E: [email protected] Guna Rajagopal, Discovery Genomics E: [email protected]

JOHNSON & JOHNSON INNOVATION | 30 Discovery and Platforms Global Public Health

Richard Tillyer, Ph.D. Ruxandra Draghia-Akli, M.D., Ph.D. Global Head, Discovery, Product Global Head, Global Public Health R&D Development & Supply (DPDS) Haresh Mirchandani Julian Bertschinger Global Head, Business Development, E: [email protected] Global Public Health Gadi Bornstein E: [email protected] Biologic Modalities, East US Gary Van Savage E: [email protected] Senior Director, Transactions Elena Diez Cecilia E: [email protected] Synthetic Modalities, East US Paul Jackson E: [email protected] Scientific Director, JumpstARter Library Lead Jay Lin E: [email protected] All Modalities, Asia Pacific Fred Tonelli E: [email protected] Senior Director, External Innovation Sarah Lively E: [email protected] Synthetic Modalities, West US, Australia, New Zealand E: [email protected]

JOHNSON & JOHNSON INNOVATION | 31 Consumer Health R&D Leadership and Business Development contacts

Global Consumer Health R&D Consumer Health Business Development

Caroline Tillett, Ph.D. Peter Kerrane Global Head, Consumer Health R&D Worldwide Vice President, Johnson & Johnson Consumer Health Strategy & Business Development E: [email protected]

Brian Shuster Consumer Health Early Stage - Innovation Centers Vice President, Consumer Business Development E: [email protected] Stefanie Dhanda Senior Director, Scientific Innovation, Consumer, East NA E: [email protected] Tyrone Mao Senior Director, Scientific Innovation, Consumer, Asia Pacific E: [email protected] Felix Reutter Senior Director, Scientific Innovation, Consumer Health, EMEA E: [email protected] Heather Barnes Manger, Scientific Innovation, Consumer Health, EMEA E: [email protected]

JOHNSON & JOHNSON INNOVATION | 32 Medical Devices R&D Leadership and Business Development contacts

Medical Devices R&D Vision R&D

Peter Shen, Ph.D. Xiao-Yu Song, M.D., Ph.D. Global Head of Research & Development, Global Head of Research & Development, Johnson & Johnson Medical Devices Companies Johnson & Johnson Vision

Medical Devices R&D Heads Vision R&D Heads

Ahmet Tezel, Ph.D. David Turner Vice President, R&D, Ethicon Head of R&D, Contact Lens Platform

Steve White MK Manohar Raheja, Ph.D. Vice President, R&D, DePuy Synthes Head of R&D, Ophthalmic Implants & Surgical Instrumentation Platform

Avi Shalgi Vice President, R&D, Cardiovascular Rajesh Rajpal, MD & Specialty Solutions CMO and VP, Medical and Clinical Affairs

Dennis Salzman, Ph.D. VP, Regulatory Affairs

Hassan Chaouk Director of External Innovation, East NA E: [email protected]

JOHNSON & JOHNSON INNOVATION | 33 Medical Devices Early Stage - Innovation Centers Medical Devices Business Development

Imran Hamid Susan Morano Senior Director, New Ventures & Transactions, Vice President, Business Development, MD, EMEA Johnson & Johnson Medical Devices Companies E: [email protected] Nicholas Mourlas Senior Director, New Ventures MD, West NA Medical Devices Business Development Heads E: [email protected] Ibraheem Badejo Peter Hawkes Senior Director, New Ventures MD, East NA Senior Director, Business Development, E: [email protected] Asia Pacific E: [email protected] Vision Early Stage - Innovation Centers Jennifer Kozak Vice President, Business Development, Prabhu Velusami Ethicon & Digital Surgery Senior Director, New Ventures E: [email protected] & Transactions, EMEA Christine Knoblauch E: [email protected] Vice President, Business Development, Andrew Pilon DePuy Synthes Senior Director, New Ventures E: [email protected] & Transaction, West NA Biren Mehta E: [email protected] Vice President, Business Development, CSS and Vision E: [email protected]

JOHNSON & JOHNSON INNOVATION | 34 Our global reach

Johnson & Johnson World Headquarters, New Jersey

Innovation Centers

Major Global R&D Locations

JLABS Locations

External Network Locations

JOHNSON & JOHNSON INNOVATION | 36 Innovation centers Major Global R&D locations

West NA & ANZ – South San Francisco, CA, USA Pharmaceuticals Consumer Health Medical Devices & Vision La Jolla, CA, USA Val-de-Reuil, France Raynham, MA, USA East NA – Boston, MA, USA Spring House, PA, USA Skillman, NJ, USA Irvine, CA, USA Beerse, Belgium Cincinnati, OH, USA EMEA – London, UK Haifa, Israel Shanghai, China APAC – Shanghai, China

JLABS locations

JLABS @ BE JLABS @ MBC JPOD @ Boston JLABS @ NYC JLABS @ TMC Beerse, Belgium BioLabs Boston, MA, USA New York, NY, USA Houston, TX, USA Bay Area, CA, USA JLABS @ Toronto JLABS @ LabCentral JPOD @ Philadelphia Toronto, Canada JLABS @ San Diego Boston, MA, USA Philadelphia, PA, USA La Jolla, CA, USA JLABS @ Shanghai JLABS @ M2D2 JLABS @ Washington DC Shanghai, China JLABS @ SSF Lowell, MA, USA Washington, D.C., USA South San Francisco, (Opening in 2021) CA, USA

External network locations

Global Public Health JJIPO @ Monash JJIPO @ QUT Ghana Melbourne, VIC, Brisbane, QLD, Australia Kenya Australia Nigeria CDI @ TMC South Africa Houston, TX, USA

JOHNSON & JOHNSON INNOVATION | 37 EMAIL US: [email protected]

VISIT OUR WEBSITE FOR MORE INFORMATION: www.jnjinnovation.com

APPLY FOR A CHALLENGE: www.jnjinnovation.com/challenges

JOHNSON & JOHNSON INNOVATION | 38